Literature DB >> 16275591

Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.

Yoshinobu Kanda1, Hisashi Sakamaki, Hiroshi Sao, Shinichiro Okamoto, Yoshihisa Kodera, Ryuji Tanosaki, Masaharu Kasai, Akira Hiraoka, Satoshi Takahashi, Shuichi Miyawaki, Takakazu Kawase, Yasuo Morishima, Shunichi Kato.   

Abstract

Little information is available regarding the effect of the conditioning regimen on the outcome of bone marrow transplantation (BMT) from an unrelated donor. Therefore, we retrospectively compared the outcome after a cyclophosphamide/total body irradiation (Cy-TBI) regimen, an intensified Cy-TBI regimen (Cy-TBI+), a busulfan and cyclophosphamide (Bu-Cy) regimen, and a Bu-Cy regimen with total lymphoid irradiation (Bu-Cy-TLI). Clinical data of 1875 adult patients who underwent unmanipulated unrelated BMT for leukemia or myelodysplastic syndrome by using 1 of the 4 regimens between 1993 and 2002 were extracted from the database of the Japan Marrow Donor Program. The effect of the conditioning regimen was adjusted for other independent significant factors by multivariate analyses. The Cy-TBI regimen was significantly better than the Bu-Cy regimen with regard to the incidence of engraftment failure (odds ratio, 2.49; P = .046) and overall survival (relative risk [RR], 1.31; P = .050). The Bu-Cy-TLI regimen decreased relapse (RR, 0.13; P = .039) but increased nonrelapse mortality (RR, 1.89; P = .0061). The Cy-TBI+ regimen resulted in increased nonrelapse mortality (RR, 1.48; P = .0003) and inferior survival (RR, 1.45; P < .0001). The results of this retrospective study suggested that the Cy-TBI regimen was superior to other regimens in unrelated BMT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275591     DOI: 10.1016/j.bbmt.2005.07.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

1.  Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Maki Hagihara; Rika Kawasaki; Etsuko Yamazaki; Hideyuki Koharazawa; Jun Taguchi; Naoto Tomita; Katsumichi Fujimaki; Rika Sakai; Hiroyuki Fujita; Shin Fujisawa; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2015-07-15       Impact factor: 2.490

2.  Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; June Takeda; Kazunari Aoki; Tadakazu Kondo; Satoshi Takahashi; Yasushi Onishi; Yukiyasu Ozawa; Nobuyuki Aotsuka; Yasuji Kouzai; Hirohisa Nakamae; Shuichi Ota; Chiaki Nakaseko; Hiroki Yamaguchi; Koji Kato; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; J Tong; B-L Tang; C-Y Zhou; W Yao; C-C Zheng; K-D Song; X-Y Zhu; W Wei; Y Wang
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

4.  Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan.

Authors:  Takaaki Konuma; Jun Ooi; Naoyuki Uchida; Hiroyasu Ogawa; Kazuteru Ohashi; Heiwa Kanamori; Nobuyuki Aotsuka; Yasushi Onishi; Hiroki Yamaguchi; Yasuji Kozai; Tokiko Nagamura-Inoue; Koji Kato; Ritsuro Suzuki; Yoshiko Atsuta; Seiko Kato; Shigetaka Asano; Satoshi Takahashi
Journal:  Haematologica       Date:  2014-09-12       Impact factor: 9.941

5.  Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation.

Authors:  Miki Sato; Shinichi Kako; Kana Matsumoto; Kumi Oshima; Yu Akahoshi; Hirofumi Nakano; Tomotaka Ugai; Ryoko Yamasaki; Hidenori Wada; Yuko Ishihara; Kana Sakamoto; Koji Kawamura; Masahiro Ashizawa; Kiriko Terasako-Saito; Shun-Ichi Kimura; Hideki Nakasone; Misato Kikuchi; Aki Tanihara; Rie Yamazaki; Yukie Tanaka; Junya Kanda; Junji Nishida; Kunihiko Morita; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2015-02-12       Impact factor: 2.490

6.  Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.

Authors:  Takaaki Konuma; Jun Ooi; Hitomi Nagayama; Akira Tomonari; Nobuhiro Tsukada; Seiko Kato; Toshiro Kawakita; Masamichi Isobe; Maki Monna-Oiwa; Arinobu Tojo; Tohru Iseki; Satoshi Takahashi
Journal:  Ann Hematol       Date:  2021-09-30       Impact factor: 3.673

7.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

8.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

9.  Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.

Authors:  Xiao-Ru Lei; Hong-Li Chen; Fang-Xia Wang; Ju Bai; Ai-Li He
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; Kazunari Aoki; June Takeda; Tadakazu Kondo; Tetsuya Eto; Shuichi Ota; Hisako Hashimoto; Takahiro Fukuda; Yukiyasu Ozawa; Yoshinobu Kanda; Chiaki Kato; Mineo Kurokawa; Koji Iwato; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Akiyoshi Takami
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.